Meeting
2020 ASCO Virtual Scientific Program
Pharmacokinetically-guided 5-FU dose optimization within the preoperative FOLFOXIRI regimen in resectable pancreatic cancer patients.
Authors
Anna Vilalta
Department of Medical Oncology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain
Anna Vilalta , Amaia Urrizola Martínez , Azucena Aldaz , Pablo Sala Elarre , Mariano Ponz-Sarvisé , Fernando Rotellar , Fernando Pardo , Jose Carlos Subtil , Ana Chopitea , Javier Rodriguez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4636)
DOI
10.1200/JCO.2020.38.15_suppl.4636
Abstract #
4636
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
The minimal effective relative dose intensity (RDI) for modified FOLFIRINOX in advanced pancreatic cancer: Suggestion for modified Hryniuk’s calculation method.
First Author: Jong-chan Lee
Poster
2016 Gastrointestinal Cancers Symposium
FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.
First Author: Jon Kroll Bjerregaard
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers